Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 06 - 16 save search
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
Published: 2021-06-16 (Crawled : 23:00) - biospace.com/
CVAC | News | $2.41 -1.23% 190K
|
Health Technology
|
| O: 0.57%
H: 2.27%
C: -4.02%
covid phase 2 vaccine phase 2b trial cv2cov covid-19
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Published: 2021-06-16 (Crawled : 23:00) - globenewswire.com
ARGX | $360.47 0.58% 45K
|
Health Technology
|
| O: -0.75%
H: 2.48%
C: 1.48%
treatment results phase 3 trial trial results lancet
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
TARS | $32.89 0.12% 200K
|
Health Technology
|
| O: 0.23%
H: 1.5%
C: 0.71%
disease phase 1 vaccine trial phase 3 phase 2
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
STSA | $1.1 -0.9% -0.91% 0
|
Health Technology
|
| O: -0.41%
H: 1.43%
C: 1.02%
phase 1 positive results trial phase 3 phase 2
Pancreatic Cancer Action Network Partners With FibroGen To Bring New Experimental Treatment Arm To Adaptive Clinical Trial, Precision Promise(SM)
Published: 2021-06-16 (Crawled : 16:00) - biospace.com/
FGEN | $1.075 -8.12% 650K
|
Health Technology
|
| O: -0.32%
H: 2.45%
C: 2.13%
treatment cancer trial pancreatic pancreas
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
APRE | $5.61 1.5K
|
Health Technology
|
| O: 50.72%
H: 6.7%
C: -26.4%
phase 1 trial phase 3 phase 2 aml
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
Published: 2021-06-16 (Crawled : 12:15) - biospace.com/
IRWD | $7.735 1.78% 480K
|
Health Technology
|
| O: 0.45%
H: 2.23%
C: 2.14%
positive results trial syndros
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
Published: 2021-06-16 (Crawled : 12:15) - biospace.com/
NVO | $123.01 0.21% 2.6M
|
Health Technology
|
| O: -0.2%
H: 0.49%
C: -0.91%
LLY | $728.765 -2.3% 1.5M
|
Health Technology
|
| O: 0.0%
H: 0.37%
C: -1.24%
ALNY | News | $146.34 0.81% 64K
|
Health Technology
|
| O: -0.03%
H: 1.15%
C: 1.11%
treatment trial
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
Published: 2021-06-16 (Crawled : 12:15) - globenewswire.com
FGEN | $1.075 -8.12% 650K
|
Health Technology
|
| O: -0.32%
H: 2.45%
C: 2.13%
cancer trial pancreatic pancreas
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -4.93%
disease phase 1 trial phase 3 phase 2
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
Published: 2021-06-16 (Crawled : 12:00) - globenewswire.com
PSTV | $1.67 -1.27% 4.6K
|
Health Technology
|
| O: 0.0%
H: 2.06%
C: 1.47%
trial approval glioblastoma
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
ALT | $6.78 -1.6% 1.4M
|
Commercial Services
|
| O: 2.19%
H: 34.76%
C: 13.99%
phase 1 positive trial phase 3 phase 2 obesity
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Published: 2021-06-16 (Crawled : 11:00) - globenewswire.com
SWTX | News | $40.555 -4.51% 180K
|
Health Technology
|
| O: 0.08%
H: 1.02%
C: -0.11%
phase 1 children trial phase 3 phase 2
Industrial Robotics Market Size to Reach USD 54.77 Billion by 2024 at a CAGR 15.17% | SpendEdge
Published: 2021-06-16 (Crawled : 07:00) - prnewswire.com
ABB | News | $37.13 -0.03% 6.4M
|
Producer Manufacturing
|
| O: -0.52%
H: 0.03%
C: -1.67%
trial
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | $894.71 0.08% 180K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
Industrial Emission Control Systems Market: COVID-19 Focused Report | Evolving Opportunities with Ducon and Durr AG | Technavio
Published: 2021-06-16 (Crawled : 02:00) - prnewswire.com
BW | News | $0.9364 -3.3% 530K
|
Electronic Technology
|
| O: -1.22%
H: 2.23%
C: 1.36%
covid trial
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.